Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) is a challenge. Thymus- and activation-regulated chemokine (TARC) has recently been reported to play a role in ABPA. The aim of this study was to compare the diagnostic value of TARC with that of known serological markers for diagnosis of ABPA in CF patients. The present study longitudinally followed 48 CF patients, of whom 12 had a diagnosis of ABPA according to Nelson's criteria, for 1–8 yrs with repeated measurements of serum total immunoglobulin (Ig)E, specific Aspergillus fumigatus IgE and IgG, specific IgE against recombinant A. fumigatus allergens (rAsp f) 1, 3, 4 and 6, and TARC. Median (interquartile range) TARC levels were 589 (465–673) pg·mL−1 in ABPA patients and 232 (189–289) pg·mL−1 in non-ABPA patients. Receiver operating characteristic curves revealed that TARC was superior to the other markers for diagnosis of ABPA. Diagnostic accuracy was greater for TARC (93%) than for total IgE (74%), or rAsp f 4 (75%) or f 6 (79%). The present study indicates that thymus- and activation-regulated chemokine may be useful in the diagnosis of allergic bronchopulmonary aspergillosis in cystic fibrosis patients. However, larger studies are needed before thymus- and activation-regulated chemokine can routinely be used in diagnostic algorithms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stevens, D. A., Moss, R. B., Kurup, V. P., Knutsen, A. P., Greenberger, P., Judson, M. A., Denning, D. W., Crameri, R., Brody, A. S., Light, M., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376525 · Cited by 790 · cited 3×
“Therefore, as stated in the most recent consensus document on diagnosis and therapy of ABPA in CF patients, serological findings should contribute strongly to the confirmation or exclusion of clinically suspected ABPA [ 5 ].”
BackgroundMethodInfluential
Cited by
Fungal allergy in asthma-state of the art and research needs
Denning, D. W., Pashley, C., Hartl, D., Wardlaw, A., Godet, C., Del Giacco, S., Delhaes, L., & Sergejeva, S. (2014) · Clinical and Translational Allergy · doi:10.1186/2045-7022-4-14 · Cited by 357
“Clinically, CCL17 may serve as a serum biomarker in patients to differentiate sensitization to Aspergillus from clinically active ABPA flares, especially when quantified longitudinally, as supported by two studies [127,128]; cutoffs are not established.”
BackgroundSelf-citationSevere asthma: from characteristics to phenotypes to endotypes
Wenzel, S. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03929.x · Cited by 336
Innate immunity in cystic fibrosis lung disease
Hartl, D., Gaggar, A., Bruscia, E., Hector, A., Marcos, V., Jung, A., Greene, C., McElvaney, G., Mall, M., & Döring, G. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.07.003 · Cited by 230
“In ABPA, the Th2-associated CC chemokines CCL17 and CCL22 have been proposed as potential biomarkers [43,128–132].”
BackgroundSelf-citationMaturu, V. N., & Agarwal, R. (2015) · Clinical & Experimental Allergy · doi:10.1111/cea.12595 · Cited by 173
“…Adults NA Major (T/I/P) Minor (W/E/S/G/R/C/SR) 19/74 2/74 2/74 Chotirmall et al. (2008) [54] Ireland, Prospective Adults CF foundation criteria 6/50 Latzin et al. (2008) [55] Switzerland, Prospective Children Nelson criteria 12/48 Rapaka et al. (2008) [56] USA, Prospective NA CF…”
Immunotherapeutic approaches to treatment of fungal diseases
Armstrong-James, D., Brown, G. D., Netea, M. G., Zelante, T., Gresnigt, M. S., van de Veerdonk, F. L., & Levitz, S. M. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30442-5 · Cited by 135
Metadata
- Authors
- Latzin, P., Hartl, D., Regamey, N., Frey, U., Schoeni, M. H., & Casaulta, C.
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2007-09-26
- Volume
- 31
- Issue
- 1
- Pages
- 36-42
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2157155364
- Cited by
- 81
- References
- 1
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. https://app.cochat.ai/papers/10.1183/09031936.00078107
- The paper
- Latzin, P., Hartl, D., Regamey, N., Frey, U., Schoeni, M. H., & Casaulta, C. (2008). Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis. European Respiratory Journal. https://doi.org/10.1183/09031936.00078107
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.